All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Orphan Drug Designation to 9MW2821 for Esophageal Cancer

May 8th 2024

The FDA has granted orphan drug designation to 9MW2821 as a potential treatment for patients with esophageal cancer.

Naumann Dives into Case-by-Case Decision-Making in Ovarian and Endometrial Cancer

May 8th 2024

R. Wendel Naumann, MD, highlights endometrial cancer case studies and how they represent changes in this treatment paradigm.

Action is Key to Continue to Break Down Barriers for Equitable Cancer Care

May 8th 2024

Experts from the University of Wisconsin Health discuss ongoing barriers to equitable cancer care and ways to drive change.

TSP May Predict Chemoresistance and Survival Outcomes in Ovarian Cancer

May 8th 2024

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic use of tumor stroma proportion for outcomes and chemoresistance in ovarian cancer.

Health Canada Approves Goserelin Acetate for High-Risk, ER+ Early and Advanced Breast Cancer

May 8th 2024

Health Canada has approved an sNDA for goserelin acetate 10.8 mg every 12 weeks for ER-positive early breast cancer with a high risk of recurrence or advanced breast cancer.

Fox Chase Researchers Examine Alternative Methods of Specialized Imaging Scans for Kidney Masses

May 8th 2024

Fox Chase Researchers Examine Alternative Methods of Specialized Imaging Scans for Kidney Masses

Awareness and Early Detection Remain Key Issues in Ovarian Cancer

May 8th 2024

Vaidehi Mujumdar, MD, discusses updates in ovarian cancer for 2024 World Ovarian Cancer Day.

Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer

May 7th 2024

R. Wendel Naumann, MD, discusses 2 case studies in platinum-resistant ovarian cancer and the optimal treatment approaches for each patient.

Second-Line Venetoclax Associated With Real-World Cost Savings vs BTK Inhibitors in CLL/SLL

May 7th 2024

Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.

Orca-T Offers Favorable Post-Transplant Outcomes in Advanced Hematologic Malignancies

May 7th 2024

Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.

Sylvester Oncologist Contributes to Global Plan to Fight Prostate Cancer

May 7th 2024

Brandon Mahal, MD, of Sylvester Comprehensive Cancer Center, was commissioned to write a collaborative article on prostate cancer for The Lancet.

Setanaxib Plus Pembrolizumab Improves Survival in Recurrent/Metastatic HNSCC

May 7th 2024

Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.

FDA Grants Priority Review to Zenocutuzumab BLA for NRG1+ NSCLC and Pancreatic Cancer

May 7th 2024

The zenocutuzumab BLA for patients with NRG1-positive non–small cell lung cancer and pancreatic cancer has received priority review from the FDA.

Loncastuximab Tesirine Elicits Responses in R/R Marginal Zone Lymphoma

May 7th 2024

Treatment with loncastuximab tesirine yielded high response rates in patients with relapsed or refractory marginal zone lymphoma.

FDA Approves Noninvasive Stool RNA Screening Test for CRC

May 7th 2024

The FDA has approved ColoSense for use as a screening test in adults 45 years of age or older who are at average risk of developing colorectal cancer.

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

May 6th 2024

No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.

UW Health Experts Underscore Value of Continuous Mentorship to Champion Women in Oncology

May 6th 2024

UW Health experts advocate for more women in leadership positions and discuss the need to cultivate diversity to reduce disparities in cancer care.

Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer

May 6th 2024

Angela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.

Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC

May 6th 2024

Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.

Agnostic Approval of Trastuzumab Deruxtecan Ushers in New Option for Advanced HER2+ Solid Tumors

May 6th 2024

Ronan J. Kelly, MD, MBA, discusses the significance of the FDA approval of trastuzumab deruxtecan for pretreated, advanced HER2-positive solid tumors.